{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T21:35:25Z","timestamp":1785447325175,"version":"3.56.0"},"reference-count":39,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2024,3,12]],"date-time":"2024-03-12T00:00:00Z","timestamp":1710201600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Brit J Clinical Pharma"],"published-print":{"date-parts":[[2024,6]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Aims<\/jats:title><jats:p>Dermatology treatments require adherence for safe and effective use. Real\u2010world healthcare databases can reveal drug utilization patterns and uncover inappropriate or unexpected use. This study aimed to analyse dermatology drug utilization patterns using epidemiological and inequality measures, leveraging Danish nationwide registries. It also assessed the feasibility of this method for detecting aberrant drug use.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>We formed a 2019 cohort of all patients treated for skin conditions through Danish healthcare registries. We calculated prevalence, incidence rates and treatment duration for dermatological drugs. Inequality in drug utilization was assessed using Lorenz curves, Gini coefficients and other measures.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>The study encompassed 1\u2009021\u2009255 patients using 94 dermatology drugs. Most usage aligned with \u2018expected clinical use\u2019, but we detected inequality, with some drugs having high Gini coefficients and disproportionate consumption by the top percentile of users. Notable findings included potential inappropriate antibiotic use, excessive topical corticosteroid use and unexpected drug use duration.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>In Denmark, dermatology drugs are used primarily as anticipated, with minimal unexpected patterns. Specific follow\u2010up is required to draw conclusions about inappropriate use. This approach demonstrates broad applicability for screening aberrant drug utilization.<\/jats:p><\/jats:sec>","DOI":"10.1111\/bcp.16037","type":"journal-article","created":{"date-parts":[[2024,3,12]],"date-time":"2024-03-12T09:44:41Z","timestamp":1710236681000},"page":"1450-1462","source":"Crossref","is-referenced-by-count":2,"title":["Screening of dermatology drugs for aberrant use\u2010patterns: An application of epidemiologic estimates and measures of inequality in drug use"],"prefix":"10.1111","volume":"90","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7224-7833","authenticated-orcid":false,"given":"Thomas","family":"Delvin","sequence":"first","affiliation":[{"name":"Clinical Pharmacology, Pharmacy and Environmental Medicine, Institute of Public Health University of Southern Denmark  Odense C Denmark"},{"name":"R&amp;D Medical Sciences LEO Pharma  Ballerup Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anette","family":"Bygum","sequence":"additional","affiliation":[{"name":"Clinical Institute University of Southern Denmark  Odense C Denmark"},{"name":"Department of Clinical Genetics Odense University Hospital  Odense C Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lars Christian","family":"Lund","sequence":"additional","affiliation":[{"name":"Clinical Pharmacology, Pharmacy and Environmental Medicine, Institute of Public Health University of Southern Denmark  Odense C Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacob Harbo","family":"Andersen","sequence":"additional","affiliation":[{"name":"Clinical Pharmacology, Pharmacy and Environmental Medicine, Institute of Public Health University of Southern Denmark  Odense C Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jesper","family":"Hallas","sequence":"additional","affiliation":[{"name":"Clinical Pharmacology, Pharmacy and Environmental Medicine, Institute of Public Health University of Southern Denmark  Odense C Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2024,3,12]]},"reference":[{"key":"e_1_2_10_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.drudis.2020.09.023"},{"key":"e_1_2_10_3_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40265\u2010020\u201001335\u20107"},{"key":"e_1_2_10_4_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.316.7141.1352"},{"key":"e_1_2_10_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2016.03.018"},{"key":"e_1_2_10_6_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10654\u2010018\u20100386\u20108"},{"key":"e_1_2_10_7_1","doi-asserted-by":"publisher","DOI":"10.1158\/2767\u20109764.CRC\u201022\u20100026"},{"key":"e_1_2_10_8_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.14982"},{"key":"e_1_2_10_9_1","doi-asserted-by":"publisher","DOI":"10.1111\/cts.13452"},{"key":"e_1_2_10_10_1","unstructured":"WHO Collaborating Centre for Drug Statistics Methodology.Definition and general considerations.https:\/\/www.whocc.no\/ddd\/definition_and_general_considera\/. Accessed May 10 2021."},{"key":"e_1_2_10_11_1","doi-asserted-by":"publisher","DOI":"10.2307\/2532312"},{"key":"e_1_2_10_12_1","doi-asserted-by":"publisher","DOI":"10.1097\/00001648\u2010199710000\u201000009"},{"key":"e_1_2_10_13_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1742\u20107843.2006.pto_257.x"},{"key":"e_1_2_10_14_1","doi-asserted-by":"publisher","DOI":"10.2307\/2276207"},{"key":"e_1_2_10_15_1","volume-title":"Memorie di metodologica statistica","author":"Gini C","year":"1912"},{"key":"e_1_2_10_16_1","doi-asserted-by":"publisher","DOI":"10.1177\/1403494811399956"},{"key":"e_1_2_10_17_1","doi-asserted-by":"publisher","DOI":"10.1111\/bph.14747"},{"key":"e_1_2_10_18_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13756\u2010021\u201000943\u20106"},{"key":"e_1_2_10_19_1","doi-asserted-by":"publisher","DOI":"10.1086\/499365"},{"key":"e_1_2_10_20_1","doi-asserted-by":"publisher","DOI":"10.1080\/14740338.2021.1902502"},{"key":"e_1_2_10_21_1","unstructured":"Vejledning om forebyggelse af spredning af MRSA [Guidance on preventing the spread of MRSA].https:\/\/www.sst.dk\/da\/udgivelser\/2023\/vejledning-om-forebyggelse-af-spredning-af-mrsa. Accessed June 4 2023."},{"key":"e_1_2_10_22_1","unstructured":"MRSA\u2014opg\u00f8relse over sygdomsforekomst 2019 [MRSA\u2014statement of disease incidence 2019].https:\/\/www.ssi.dk\/sygdomme-beredskab-og-forskning\/sygdomsovervaagning\/m\/mrsa-2019. Accessed April 28 2023."},{"key":"e_1_2_10_23_1","volume-title":"StatPearls","author":"Murphy PB","year":"2023"},{"key":"e_1_2_10_24_1","doi-asserted-by":"publisher","DOI":"10.3390\/antibiotics12020188"},{"key":"e_1_2_10_25_1","unstructured":"US Centers for Disease Control and Prevention.Antibiotic resistance threats in the United States 2019.US Centers for Disease Control and Prevention;2019.10.15620\/cdc:82532"},{"key":"e_1_2_10_26_1","first-page":"1","article-title":"Behandling af akne med fokus p\u00e5 antibiotika og resistens: hvordan kan vi reducere forbruget? [Treatment of acne with a focus on antibiotics and resistance: how can we reduce consumption?]","volume":"8","author":"Lomholt AHB","year":"2014","journal-title":"Rationel Farmakoterapi"},{"key":"e_1_2_10_27_1","doi-asserted-by":"publisher","DOI":"10.1080\/09546634.2023.2200570"},{"key":"e_1_2_10_28_1","doi-asserted-by":"publisher","DOI":"10.1080\/09546634.2023.2202288"},{"key":"e_1_2_10_29_1","doi-asserted-by":"publisher","DOI":"10.2340\/00015555\u20102918"},{"key":"e_1_2_10_30_1","doi-asserted-by":"publisher","DOI":"10.4103\/2229\u20105178.142483"},{"key":"e_1_2_10_31_1","doi-asserted-by":"publisher","DOI":"10.1034\/j.1600\u20100625.2000.009003165.x"},{"key":"e_1_2_10_32_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2005.01.010"},{"key":"e_1_2_10_33_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2020.4968"},{"key":"e_1_2_10_34_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc18\u20102158"},{"key":"e_1_2_10_35_1","first-page":"36","article-title":"Topical steroid withdrawal in atopic dermatitis","author":"Lio P","year":"2019","journal-title":"Practical Dermatol"},{"key":"e_1_2_10_36_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40261\u2010021\u201001072\u2010z"},{"key":"e_1_2_10_37_1","doi-asserted-by":"publisher","DOI":"10.1111\/myc.13426"},{"key":"e_1_2_10_38_1","doi-asserted-by":"publisher","DOI":"10.1093\/ije\/dyw213"},{"key":"e_1_2_10_39_1","doi-asserted-by":"publisher","DOI":"10.1093\/ije\/dyw116"},{"key":"e_1_2_10_40_1","unstructured":"WHO Collaborating Centre for Drug Statistics Methodology Guidelines for ATC classification and DDD assignment 2020. Oslo 2019.https:\/\/www.whocc.no\/filearchive\/publications\/2020_guidelines_web.pdf. Accessed February 20 2020."}],"container-title":["British Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bcp.16037","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,30]],"date-time":"2024-05-30T12:17:49Z","timestamp":1717071469000},"score":1,"resource":{"primary":{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/10.1111\/bcp.16037"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,12]]},"references-count":39,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2024,6]]}},"alternative-id":["10.1111\/bcp.16037"],"URL":"https:\/\/doi.org\/10.1111\/bcp.16037","archive":["Portico"],"relation":{},"ISSN":["0306-5251","1365-2125"],"issn-type":[{"value":"0306-5251","type":"print"},{"value":"1365-2125","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,3,12]]}}}